Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565751 | 0.88 | KDM4E (0.38) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL9911336 | 0.86 | PIK3CD (0.38) | PIK3CDCHRNB2CHRNA4 | |
| SCHEMBL25963452 | 0.84 | HTR1D (0.36) | KDM4EALDH1A1PIK3CDKDM5AKDM4C | |
| SCHEMBL25565770 | 0.84 | CHRM2 (0.37) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL15511354 | 0.83 | ATM (0.32) | ATM | |
| SCHEMBL22510247 | 0.82 | SLC6A2 (0.39) | PIK3CDCHRNB2CHRNA4 | |
| SCHEMBL25565768 | 0.81 | CHRM2 (0.39) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL25075497 | 0.80 | PIK3CD (0.43) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL20970411 | 0.80 | KDM4E (0.34) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL12028002 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| EP-2708529-B1 | METHOD FOR MANUFACTURING PARTICLES | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9796831-B2 | Process for producing particles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| CN-103534236-B | Method for producing granules | 住友化学株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-103974929-A | Method for producing hydrohalic acid salt of halogenated alkyl amine | SUMITOMO CHEMICAL CO | 2014-08-06 | — | — | CN | disclosed |
| EP-2708529-A1 | METHOD FOR MANUFACTURING PARTICLES | Sumitomo Chemical Company Limited (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20140065337-A1 | PROCESS FOR PRODUCING PARTICLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| CN-103534236-A | Method for producing granules | SUMITOMO CHEMICAL CO | 2014-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | KDM4E 4039/4885ALDH1A1 3174/4885PIK3CD 987/4885 |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | KDM4E 2222/4885ALDH1A1 2673/4885PIK3CD 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.